BioNTech and Bristol Myers Squibb Launch Global Partnership to Develop Innovative Cancer Therapies with BNT327

BioNTech SE and Bristol Myers Squibb announced a major global strategic partnership. Together, they will co-develop and commercialize the bispecific antibody candidate BNT327 to treat a wide range of solid tumors.

BNT327 is an advanced-stage clinical immunotherapy candidate that combines two validated mechanisms into a single molecule: PD-L1 checkpoint inhibition and VEGF-A neutralization. This innovative approach aims to provide new treatment options for patients with hard-to-treat cancers.

The partnership is based on a 50:50 profit and loss split, covering both clinical development and potential commercialization. Over 20 studies are already underway or in preparation, including global Phase 3 trials for small cell and non-small cell lung cancer, as well as triple-negative breast cancer (TNBC).

“BNT327 could become a cornerstone of immuno-oncology,” said Prof. Ugur Sahin, CEO of BioNTech. Christopher Boerner, CEO of Bristol Myers Squibb, added: “Together, we have the potential to fundamentally change the standard of care for solid tumors.”

Under the agreement, BMS will make an upfront payment of $1.5 billion to BioNTech, in addition to up to $7.6 billion in potential milestone payments. Both companies retain the right to independently develop BNT327 in other indications and combinations, including assets from their own pipelines.

BNT327 enhances the companies’ positions as leaders in immuno-oncology. By targeting the tumor microenvironment, the therapy aims not only to halt tumor growth but also to boost the immune system’s response – a potential turning point in cancer treatment.